Big Money Sentiment Indicator of Corcept Therapeutics Inc (NASDAQ:CORT) Crashed in Q2 2018 to 1.18

Corcept Therapeutics Incorporated (NASDAQ:CORT) Corporate Logo

Corcept Therapeutics Inc’s Sentiment

In 2018 Q2 Corcept Therapeutics Inc (NASDAQ:CORT) big money sentiment decreased to 1.18, SEC.gov filings reveal. That’s down -0.10, from 2018Q1’s 1.28. 97 hedge funds increased and opened new stock positions, while 82 sold and reduced their stock positions in Corcept Therapeutics Inc so the sentiment has dropped. These funds own 85.22 million shares, that’s up from 84.82 million shares in 2018Q1. Funds holding Corcept Therapeutics Inc in top 10 decreased from 4 to 2 for a decrease of 2. In total 23 funds closed positions, 59 reduced and 64 increased. Also 33 funds bought new Corcept Therapeutics Inc stakes.

Largest Corcept Therapeutics Inc Investors

As of 2018 Q2 Ingalls & Snyder Llc has 5.34% invested in Corcept Therapeutics Inc. As of 2018 Q2, 4.63 million shares of Corcept Therapeutics Inc are owned by Consonance Capital Management Lp. Moreover, Tanaka Capital Management Inc reported 88,154 shares in Corcept Therapeutics Inc equivalent to 3.32% of its portfolio. S&T Bank Pa revealed 397,769 shares position in Corcept Therapeutics Inc. The Ohio-based fund Shaker Investments Llc Oh looks positive on Corcept Therapeutics Inc, owning 107,640 shares.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.The firm is worth $1.51 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.The P/E ratio is 10.92. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

At traded at $13.04 lastly.Since December 8, 2017 it’s 21.11% down thus downtrending. CORT underperformed by 36.73% the S&P 500.

Corcept Therapeutics Incorporated (NASDAQ:CORT)’s earnings report is awaited on February, 28., as reported by Faxor. earnings per share of $0.17 is 0.00 % from 2017’s $0.17 EPS. If $0.17 is reported, CORT’s profit will be $19.63 million for 19.18 P/E. Analysts at Wall Street see Corcept Therapeutics Incorporated’s 21.43 % EPS growth compared to $0.14 earnings per share for previous quarter.

178,900 are held by Swiss Bank & Trust. Moreover, Raymond James And Assocs has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Kbc Group Nv has 369,140 shs. Ameritas Invest Prtn Inc has 8,144 shs for 0.01% of their capital. Dana Inv Advsr has invested 0.08% in Corcept Therapeutics Incorporated (NASDAQ:CORT). 57,179 are held by Zebra Cap Management Ltd Liability. Arizona State Retirement accumulated 139,202 shs. Legal & General Group Inc Pcl holds 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 208,388 shs. California-based Sand Hill Advsr Ltd Company has invested 0.02% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Wellington Mgmt Ltd Liability Partnership reported 0% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT). Dimensional Fund Limited Partnership has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Timpani Capital Management Ltd Co reported 0.37% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT). Zurcher Kantonalbank (Zurich Cantonalbank) has 5,183 shs. Principal Financial Grp Incorporated invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). 127,904 are owned by Millennium Management Limited Co.

Corcept Therapeutics Incorporated registered $4.85 million net activity with 4 insider purchases and 4 selling transactions since June 7, 2018. Shares for $105,538 were sold by FISHMAN ROBERT S.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Total analysts of 2 have positions in Corcept Therapeutics Inc (NASDAQ:CORT) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since June 12, 2018 according to StockzIntelligence Inc Corcept Therapeutics Inc has 4 analyst reports. On Tuesday, June 12 the company was maintained by FBR Capital. The company rating was maintained by FBR Capital on Tuesday, June 19. On Monday, August 13 the rating was maintained by FBR Capital with “Buy”.

For more Corcept Therapeutics Incorporated (NASDAQ:CORT) news announced recently go to: Seekingalpha.com, Nasdaq.com, Seekingalpha.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Corcept Therapeutics’ (CORT) CEO Joseph Belanoff on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” announced on May 08, 2018, “Corcept Initiates Phase III Study for Cushing’s Syndrome – Nasdaq” on November 20, 2018, “Corcept slips 3% on tentative FDA nod for Teva’s generic mifepristone – Seeking Alpha” with a publish date: October 18, 2018, “Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates – Nasdaq” and the last “Corcept Therapeutics – Speculative Buy After Fears On Generic Competition – Seeking Alpha” with publication date: February 11, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.